why choose us

300×250 Ad Slot

Research Article: Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

Date Published: 2023-05-11

Abstract:
Background: Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical practice is still limited. Here, we aimed to provide real-world data on secukinumab use, effectiveness, and persistence in axSpA.

No summary available.

300×250 Ad Slot